Light-based treatment for Sezary syndrome patients
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a special light treatment done outside the body (extracorporeal photopheresis) can help people with Sezary syndrome. It is meant to see if the treatment is safe and effective for this specific type and stage of skin lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Sezary syndrome, stage IVA1.
- You are able to receive extracorporeal photopheresis (the study’s light treatment).
- You finished any other cancer medicines at least 3 weeks ago, and you are well enough to continue.
- Any side effects from your last treatment must be mild (no worse than grade 1).
- You can sign an informed consent form and understand what the study involves.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This Phase 2 study tests how brentuximab vedotin should be dosed for people with mycosis fungoides or Sezary syndrome (skin T-cell lymphoma), and also for lymphomatoid papulosis. It may help improve how well the treatment works while tracking side effects.
This study looks at a new blood test that might help doctors diagnose Sézary syndrome (a rare type of skin lymphoma) and see how well treatment is working. It also checks for leftover disease after treatment.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
Hear when a new Sezary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.